博安生物(06955.HK)BA1302完成中国Ia期临床研究

阿斯达克财经

08/16

博安生物(06955.HK) 公布，公司自主研发的靶向CD228的创新抗体偶联药物BA1302已完成中国I期临床研究单药剂量递增阶段“Ia期”。结果显示，BA1302在经多线治疗后疾病仍进展的多种晚期实体瘤患者中展现出良好的抗肿瘤活性，整体安全耐受性良好。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-08-14 16:25。)AASTOCKS新闻

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2659561177"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2659561177\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2659561177?lang=zh_CN&edition=fundamental","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20250730181922236_s.png","is_english":false,"pubTime":"2026-08-16 21:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2659561177","market":"sh","top_or_hot":-1,"title":"博安生物(06955.HK)BA1302完成中国Ia期临床研究","media":"阿斯达克财经","content":"<div>\n<p>博安生物(06955.HK) 公布，公司自主研发的靶向CD228的创新抗体偶联药物BA1302已完成中国I期临床研究单药剂量递增阶段“Ia期”。结果显示，BA1302在经多线治疗后疾病仍进展的多种晚期实体瘤患者中展现出良好的抗肿瘤活性，整体安全耐受性良好。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-08-14 16:25。)AASTOCKS新闻</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1538527/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>博安生物(06955.HK)BA1302完成中国Ia期临床研究</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n博安生物(06955.HK)BA1302完成中国Ia期临床研究\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-16 21:46 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1538527/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>博安生物(06955.HK) 公布，公司自主研发的靶向CD228的创新抗体偶联药物BA1302已完成中国I期临床研究单药剂量递增阶段“Ia期”。结果显示，BA1302在经多线治疗后疾病仍进展的多种晚期实体瘤患者中展现出良好的抗肿瘤活性，整体安全耐受性良好。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-08-14 16:25。)AASTOCKS新闻</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1538527/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06955","symbol_name":"博安生物","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1538527/latest-news/AAFN","article_id":"2659561177","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20250730181922236_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1538527/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2659561177","pubTimestamp":1786887960,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"博安生物(06955.HK) 公布，公司自主研发的靶向CD228的创新抗体偶联药物BA1302已完成中国I期临床研究单药剂量递增阶段“Ia期”。结果显示，BA1302在经多线治疗后疾病仍进展的多种晚期实体瘤患者中展现出良好的抗肿瘤活性，整体安全耐受性良好。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-08-14 16:25。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"06955":"博安生物","BK1161":"生物科技"},"translate_title":"Boan Biotech (06955.HK) BA1302 Completed Phase Ia Clinical Study in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06955":1.5},"content_text":"博安生物(06955.HK) 公布，公司自主研发的靶向CD228的创新抗体偶联药物BA1302已完成中国I期临床研究单药剂量递增阶段“Ia期”。结果显示，BA1302在经多线治疗后疾病仍进展的多种晚期实体瘤患者中展现出良好的抗肿瘤活性，整体安全耐受性良好。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-08-14 16:25。)AASTOCKS新闻","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}